A sugar-free, self-disintegrating calcium tablet and its preparation method

By constructing a three-dimensional synergistic structure of a glassy sugar alcohol porous framework, pH-sensitive CO2 microcapsules, and phosphorylated peptide-calcium salt nanocomplex, the problems of child compliance and intestinal targeted absorption of sugar-free calcium tablets were solved, achieving efficient targeted release of CO2 and low leakage rate.

CN123101477APending Publication Date: 2026-11-17独角犀材料科技(成都)有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611298295.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-26
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing sugar-free calcium tablets have shortcomings in terms of child compliance and intestinal targeted absorption, and have a high CO2 leakage rate during storage, making it impossible to achieve intestinal-targeted release of active ingredients.

Method used

Employing a three-dimensional synergistic structure composed of a glassy sugar alcohol porous framework, pH-sensitive CO2 microcapsules, and phosphorylated peptide-calcium salt nanocomposites, a dual barrier is formed through electrostatic repulsion and size matching to prevent CO2 gas diffusion and leakage, and to achieve targeted release in the intestinal environment.

Benefits of technology

It improves children's compliance, enhances calcium absorption efficiency, reduces CO2 leakage rate, is suitable for children, diabetic patients and people with swallowing difficulties, and meets pharmaceutical GMP standards.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention belongs to the field of functional food and pharmaceutical preparation technology, specifically relating to a sugar-free self-disintegrating calcium tablet and its preparation method. The sugar-free self-disintegrating calcium tablet comprises: a porous framework composed of a sugar alcohol matrix material with vitrification capability; CO2 microcapsules dispersed in the framework; a phosphorylated polypeptide-calcium salt nanocomposite dispersed in the framework; and optional acid source particles and edible additives. The calcium tablet provided by this invention achieves high CO2 retention, a gradual oral microbubble sensation, and localized disintegration and efficient calcium absorption in the small intestine by constructing a three-dimensional synergistic structure of "glassy sugar alcohol porous framework-pH-responsive CO2 microcapsules-charge and size-matched nanocomposite," making it particularly suitable for children, diabetic patients, and people with swallowing difficulties.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of functional food and pharmaceutical preparation technology, specifically relating to a sugar-free self-disintegrating calcium tablet and its preparation method. Background Technology

[0002] Sugar-free calcium tablets are mainly divided into two categories: 1. Ordinary chewable tablets / lozenges: These require active chewing, resulting in poor compliance among children and a monotonous taste; 2. Orally disintegrating tablets (ODT): These rely on disintegrants such as croscarmellose sodium, and the disintegration process has no taste experience. Calcium ions are released in the mouth, making it impossible to achieve targeted absorption in the intestines.

[0003] The technology behind popping candy involves boiling sugar at 150-155℃ and aerating at 5-7MPa, resulting in a CO2 content of only 0.5-1.0wt%. Furthermore, CO2 is primarily absorbed through physical adsorption within the candy, leading to a leakage rate as high as 40-60% during storage. Disintegration relies solely on sugar dissolution, lacking pH selectivity and failing to achieve targeted release of active ingredients into the intestines. Additionally, the high-temperature boiling process destroys heat-sensitive nutrients such as vitamin D3.

[0004] While the use of phosphorylated peptides (such as casein phosphopeptide CPP) to promote calcium absorption is a well-known technology, existing products are mostly simple physical blends that do not form stable structured carriers, resulting in limited improvements in bioavailability (typically only 20-30%). Meanwhile, preventing the diffusion and leakage of microbubbles during storage while ensuring targeted release into the small intestine remains a technical bottleneck in the preparation of high-performance self-disintegrating calcium tablets. Summary of the Invention

[0005] To address the shortcomings of existing technologies, this invention provides a sugar-free, self-disintegrating calcium tablet and its preparation method. By constructing a three-dimensional synergistic structure of "glassy sugar alcohol porous framework-pH-responsive CO2 microcapsules-charge and size-matched nanocomposite", it achieves high CO2 retention, progressive oral microbubble sensation, and efficient absorption via small intestinal localization, making it particularly suitable for children, diabetic patients, and people with swallowing difficulties.

[0006] The technical solution adopted in this invention is as follows:

[0007] In a first aspect, the present invention provides a sugar-free, self-disintegrating calcium tablet comprising:

[0008] A porous framework composed of sugar alcohol matrix materials with vitrification capability;

[0009] CO2 microcapsules dispersed in the porous framework, wherein the CO2 microcapsules are composed of a pH-sensitive enteric material encapsulating CO2 gas, and have a particle size of 10-50 μm; and

[0010] The phosphorylated polypeptide-calcium salt nanocomposite dispersed in the porous framework has a particle size of 50-200 nm and a zeta potential of -25 to -35 mV. It fills the pores and gaps around the CO2 microcapsules in the porous framework, forming electrostatic repulsion and size gradation effect with the CO2 microcapsules to block the diffusion and leakage of CO2 gas.

[0011] As used herein, a sugar alcohol matrix material with vitrification capability refers to a sugar alcohol matrix material that can form an amorphous glassy porous structure under low-temperature rapid freezing conditions (e.g., at -40°C to -30°C). For example, such a sugar alcohol matrix material may be selected from at least one of isomaltitol and maltitol.

[0012] Preferably, the sugar alcohol matrix material is isomaltose.

[0013] Furthermore, the porosity of the porous skeleton is 40-60%.

[0014] Furthermore, the sugar alcohol matrix material has a mass percentage content of 85.0-92.0% in the sugar-free self-disintegrating calcium tablets.

[0015] Furthermore, the CO2 mass percentage content in the CO2 microcapsules is 15-25%.

[0016] Furthermore, the CO2 microcapsules have a mass percentage content of 2.0-4.0% in the sugar-free self-disintegrating calcium tablets.

[0017] Further, the pH-sensitive enteric material is Eudragit S100, or a mixture of Eudragit S100 and Eudragit FS30D in a mass ratio of (6-8):(2-4).

[0018] Furthermore, the pH-sensitive enteric material is a mixture of Eudragit S100 and Eudragit FS30D, and the pH-sensitive enteric material begins to dissolve and disintegrate in an intestinal environment with pH ≥ 6.8.

[0019] Furthermore, the phosphorylated polypeptide-calcium salt nanocomposite is formed by the self-assembly of phosphorylated polypeptide and calcium salt; the self-assembly is mainly driven by the coordination between the phosphate group of the phosphorylated polypeptide and the calcium ion, and is completed by electrostatic interaction and hydrogen bonding.

[0020] Furthermore, the molecular weight of the phosphorylated polypeptide is 1000-3000 Da.

[0021] Furthermore, the phosphorylated polypeptide is selected from at least one of casein phosphopeptide and phosphorylated serine peptide.

[0022] Furthermore, the calcium salt is selected from one or more of calcium carbonate and calcium citrate.

[0023] Furthermore, in the phosphorylated polypeptide-calcium salt nanocomposite, the molar ratio of calcium ions participating in coordination to phosphorylated polypeptides is 1:(1.5-2.5).

[0024] Furthermore, the phosphorylated polypeptide accounts for no less than 20% of the mass percentage in the nanocomposite.

[0025] Furthermore, the phosphorylated polypeptide-calcium salt nanocomposite has a mass percentage content of 5.0-10.0% in the sugar-free self-disintegrating calcium tablets.

[0026] Furthermore, the sugar-free self-disintegrating calcium tablets also contain solid organic acid particles dispersed in the matrix.

[0027] Furthermore, the solid organic acid particles are selected from at least one of anhydrous citric acid, malic acid, and tartaric acid, and their mass percentage in the sugar-free self-disintegrating calcium tablets is 0.1-0.5%.

[0028] Furthermore, the sugar-free self-disintegrating calcium tablets also contain edible additives, selected from, but not limited to, at least one of vitamin D3, flavoring, and coloring.

[0029] Furthermore, the CO2 production of the sugar-free self-disintegrating calcium tablets is <0.5 mg / tablet in the oral stage and 2-3 mg / tablet in the intestinal stage.

[0030] In a second aspect, the present invention provides a method for preparing sugar-free, self-disintegrating calcium tablets as described herein, comprising the following steps:

[0031] (1) Prepare phosphorylated polypeptide-calcium salt nanocomposite powder and CO2 microcapsule powder respectively;

[0032] (2) Mix sugar alcohol matrix material with water at a mass ratio of 5:1 to 8:1, heat to 80-90℃ to dissolve, and vacuum concentrate to a water content of ≤3wt% to obtain syrup;

[0033] (3) Cool the syrup to 40℃±2℃, and under vacuum conditions of 0.06-0.09MPa and 10-50rpm, add the nanocomposite powder, the CO2 microcapsule powder, optional solid organic acid particles and optional edible additives in sequence for vacuum mixing.

[0034] (4) The mixture obtained in step (3) is rapidly frozen at -40°C to -30°C to form an amorphous glassy porous framework for the sugar alcohol matrix material;

[0035] (5) The material after quick-freezing is vacuum dried at 20-30℃ and vacuum degree ≤10Pa until the moisture content is less than 1.5wt%, and then demolded.

[0036] Further, in step (1), the phosphorylated polypeptide-calcium salt nanocomposite is prepared as follows: the phosphorylated polypeptide and calcium salt are mixed in water, the solid content is controlled at 10-20 wt%, the pH is adjusted to 6.5-7.5, and the mixture is stirred at 25-35℃ for 1-3 hours to complete coordination self-assembly. The resulting solution is then spray-dried to obtain nanocomposite powder. Preferably, the solid content is 15%, the pH is 7.0±0.2, and the stirring temperature is 30℃.

[0037] Furthermore, the coordination self-assembly includes, but is not limited to, coordination interactions, electrostatic interactions, and hydrogen bonding interactions.

[0038] Further, in step (1), the CO2 microcapsules are prepared as follows: a pH-sensitive enteric-coated material is dissolved in an alcohol-based organic solvent to prepare a 5-10 wt% wall material solution; using coaxial spray drying technology, food-grade CO2 gas is introduced into the inner channel at a pressure of 4-5 MPa and a flow rate of 2-3 L / min, while the wall material solution is introduced into the outer channel, so that the CO2 gas is encapsulated by the wall material solution to form microcapsules. The nozzle of the coaxial spray drying has an inner diameter of 0.3-0.8 mm, an outer diameter of 1.0-1.5 mm, and a wall thickness of 0.2-0.5 mm. Preferably, the wall material solution concentration is 8 wt%, the pressure is 4.5 MPa, the flow rate is 2.5 L / min, the nozzle has an inner diameter of 0.5 mm, an outer diameter of 1.2 mm, and a wall thickness of 0.35 mm.

[0039] Beneficial effects of the present invention

[0040] Breakthrough in novelty: For the first time, a nanocomposite with a particle size of 50-200nm and a negative charge (Zeta potential -25 to -35mV) is densely filled around a 10-50μm CO2 microcapsule, forming a dual barrier of "electrostatic repulsion and size gradation", which increases the CO2 gas diffusion tortuosity to above 3.5 (measured by a gas permeameter), which is fundamentally different from popping candy and ordinary oral disintegrating tablets.

[0041] Significantly improved child compliance: By adding trace amounts of solid organic acids, a microbubble sensation in the mouth can be provided, making medication more fun. Clinical data shows that the rate of children aged 3-12 years taking medication voluntarily increased from 32% to 89%.

[0042] Calcium absorption efficiency is doubled: The enteric coating dissolves and disintegrates in the small intestine, and the main dose of CO2 (2-3 mg / tablet) is released explosively to drive the disintegration of the calcium tablet. Phosphorylated peptides are released simultaneously with calcium ions, increasing bioavailability by 60-120% and reducing the single dose.

[0043] Excellent stability: Microencapsulated CO2 has a retention rate of >85% in accelerated testing and a shelf life of up to 24 months, solving the problem of easy leakage in popping candy technology.

[0044] High process safety: Low-temperature vacuum drying replaces high-temperature and high-pressure gas filling, eliminating safety risks in the production process, meeting pharmaceutical GMP standards, and reducing energy consumption by 40%.

[0045] Expanded target population: The sugar-free formula is suitable for diabetic patients; its disintegration does not rely on large amounts of saliva, making it suitable for Sjögren's syndrome and elderly patients with dysphagia. Detailed Implementation

[0046] In a preferred embodiment, the present invention provides a sugar-free, self-disintegrating calcium tablet, which is composed of the following components in concert:

[0047] Isomaltitol porous framework: serving as a disintegration matrix and sweetness source;

[0048] pH-responsive disintegration system: It consists of independently prepared CO2 microcapsules and phosphorylated peptide-calcium salt nanocomposites, both of which are independently dispersed in a porous framework; the enteric coating material of the CO2 microcapsules is pH-sensitive polyacrylic acid resin.

[0049] Optional acid source barrier: a blend of trace amounts of solid organic acids (such as anhydrous citric acid) and isomaltitol to provide an initial microbubble sensation in the mouth.

[0050] In another preferred embodiment, the present invention provides a method for preparing sugar-free, self-disintegrating calcium tablets, comprising the following steps:

[0051] (1) The phosphorylated peptide and calcium salt are mixed in water with a solid content of 10-20%, the pH is adjusted to 6.5-7.5, and the mixture is stirred at 25-35℃ for 1-3 hours to allow the phosphorylated peptide and calcium salt to form a nanocomposite solution through self-assembly; the obtained nanocomposite solution is spray-dried to obtain nanocomposite powder with a particle size of 50-200 nm and a Zeta potential of -25 to -35 mV, wherein the particle size is determined by dynamic light scattering (DLS) and the Zeta potential is determined by electrophoretic light scattering; preferably, the solid content is 15%, the pH is 7.0±0.2, and the stirring temperature is 30℃;

[0052] (2) Dissolve the pH-sensitive enteric material in an organic solvent to prepare a wall material solution with a concentration of 5-10 wt%; use coaxial spray drying technology (inner layer CO2 gas, outer layer enteric solution), introduce food-grade CO2 gas into the inner channel at a pressure of 4-5 MPa and a flow rate of 2-3 L / min, and introduce the wall material solution into the outer channel, so that the CO2 gas is encapsulated by the wall material solution to form microcapsules, and obtain CO2 microcapsule powder; preferably, the wall material solution concentration is 8 wt%, the pressure is 4.5 MPa, the flow rate is 2.5 L / min, the inner diameter of the nozzle of the coaxial spray drying is 0.3-0.8 mm, the outer diameter is 1.0-1.5 mm, and the wall thickness is 0.2-0.5 mm; preferably, the inner diameter of the nozzle of the coaxial spray drying is 0.5 mm, the outer diameter is 1.2 mm, and the wall thickness is 0.35 mm;

[0053] (3) Mix sugar alcohol matrix material with water at a mass ratio of 5:1 to 8:1, heat to 80-90℃ to dissolve, and vacuum concentrate until the water content is ≤3%;

[0054] (4) Cool the syrup to 40℃±2℃, and add nanocomposite powder, CO2 microcapsule powder, optional acid source particles and optional edible additives in sequence, and mix under vacuum conditions; preferably, the vacuum degree of the vacuum conditions is 0.06-0.09MPa, and the mixing is carried out at 10-50rpm;

[0055] (4) Quick-freeze the mixture into shape, wherein the quick-freezing temperature is -40°C to -30°C;

[0056] (5) Vacuum dry and demold to obtain the product.

[0057] Microencapsulated CO2-pH responsive system

[0058] This invention employs a spray drying method to encapsulate CO2 gas within an enteric coating material (Eudragit S100), forming micron-sized microcapsules (particle size 10-50 μm). The microcapsules contain 15-25 wt% CO2, significantly improving storage stability (CO2 retention rate >85% after 6 months at 25℃ / 75% RH). The enteric coating dissolves when the small intestine pH is ≥7.0, releasing CO2 to drive the disintegration of calcium salts.

[0059] In the preparation of CO2 microcapsules, the inner diameter of the nozzle for coaxial spray drying is 0.3-0.8 mm, preferably 0.5 mm, the outer diameter is 1.0-1.5 mm, preferably 1.2 mm, and the wall thickness is 0.2-0.5 mm, preferably 0.35 mm. This nozzle size is crucial for achieving a particle size of 10-50 μm and an encapsulation rate of 15-25 wt%. If the wall thickness is >0.5 mm, the CO2 diffusion path is too long, resulting in an encapsulation rate <10%; if the wall thickness is <0.2 mm, the mechanical strength is insufficient, leading to a storage leakage rate >50%.

[0060] Furthermore, these nozzle parameters must work in synergy with a pressure of 4-5 MPa and a CO2 flow rate of 2-3 L / min. Experiments show that when using the preferred nozzle (0.5 mm inner diameter, 0.35 mm wall thickness), if the pressure is below 4 MPa, the amount of CO2 dissolved in the wall material solution is insufficient, resulting in an encapsulation rate of less than 12%; if the pressure is above 5 MPa, it easily leads to the breakage of atomized droplets. Similarly, the production capacity is low when the flow rate is below 2 L / min, and the microcapsule breakage rate exceeds 30% when it is above 3 L / min. Therefore, the pressure, flow rate, and nozzle structural parameters of this invention are interrelated and synergistically optimized as a whole, jointly ensuring the achievement of high encapsulation rate and high stability.

[0061] In the preparation of CO2 microcapsules, the optimal combination of CO2 gas flow rate (2-3 L / min, preferably 2.5 L / min) and pressure (4-5 MPa, preferably 4.5 MPa) allows the microcapsule wall material to form a suitable gas barrier structure, ensuring both CO2 loading (15-25 wt%) and maintaining the mechanical strength of the microcapsules. Simultaneously, the microcapsule particle size (10-50 μm) prepared under these parameters creates a size distribution effect with the subsequently added nanocomposite particle size (50-200 nm). The nanocomposite fills the area around the microcapsules and within the framework pores, increasing the tortuosity of the CO2 molecule diffusion path through dense packing, thereby reducing the leakage rate during storage. When the flow rate is >3 L / min, the microcapsule rupture rate is >30%; when the pressure is <4 MPa, the CO2 dissolution is insufficient.

[0062] In the preparation of CO2 microcapsules, the concentration of pH-sensitive enteric coating material in organic solvents is 5-10 wt%. Too high a concentration results in an excessively thick enteric coating (disintegration hysteresis > 120 minutes), while too low a concentration fails to completely encapsulate the CO2 bubbles. The preferred concentration is 8 wt%, which represents a balance between the solubility of Eudragit S100 and its film-forming properties during spray drying.

[0063] Phosphorylated peptide-calcium salt self-assembled nanocomplex

[0064] Phosphorylated serine peptides with specific molecular weights (1000-3000 Da) self-assemble with calcium carbonate via coordination bonds to form nanoparticles (50-200 nm in diameter), with a calcium-peptide molar ratio of 1:1.5-1:2.5. This structure acts as both a calcium ion carrier and synergistically with CO2 microcapsules to prevent CO2 leakage. The mechanism for preventing leakage is as follows: the nanocomposite is dispersed in a porous framework, filling the pores and gaps around the microcapsules. Its zeta potential (-25 to -35 mV) generates electrostatic repulsion with the negatively charged groups of the microcapsule wall material, causing the nanocomposite to be uniformly distributed around the microcapsules rather than agglomerated, forming a dense physical barrier layer. Simultaneously, the particle size (50-200 nm) of the nanoparticles and the pore size of the framework create a graded filling effect. Together, these factors increase the tortuosity of the path for CO2 molecules to diffuse from the microcapsules to the tablet surface to above 3.5 (measured by a gas permeameter), thereby reducing gas permeability by 80%.

[0065] In the phosphorylated peptide-calcium salt nanocomposite, the molecular weight of the phosphorylated peptide ranges from 1000 to 3000 Da, which is the core for forming stable nanoparticles. If the molecular weight is too low, effective coordination is impossible; if it is too high, the particle size exceeds 500 nm, resulting in a loss of compact filling. More importantly, the inventors discovered a synergistic effect between the zeta potential and particle size of the nanocomposite. Only when the particle size is controlled within 50-200 nm and the zeta potential is maintained within the range of -25 to -35 mV can the nanocomposite form an effective "electrostatic repulsion-size matching" double-dense filling layer with the inner wall of the CO2 microcapsule. Comparative experiments show that when the absolute value of the zeta potential is below 25 mV (e.g., -20 mV), even with a particle size of around 100 nm, the electrostatic repulsion is insufficient, and the CO2 leakage rate increases by 28%; when the particle size is greater than 200 nm (e.g., 300 nm), even with a zeta potential of -30 mV, the size matching effect fails, failing to effectively fill the microcapsule pores, and the CO2 leakage rate increases by 32%. Only when both parameters are within the range defined by this invention can the curvature of the CO2 molecule diffusion path be increased to above 3.5 and the permeability reduced by 80%, which is one of the key innovations of this invention.

[0066] In preparing phosphorylated peptide-calcium salt nanocomposites, an excess of calcium salt is used to ensure sufficient coordination of the peptides; for example, in the examples, the mass ratio of phosphorylated peptide to calcium carbonate is 1:3. In the formed nanocomposites, the molar ratio of calcium ions actually involved in coordination to peptides is 1:1.5-1:2.5. This molar ratio directly determines the coordination saturation and surface charge density of the nanocomposites. When the molar ratio deviates from this range, either insufficient peptides lead to calcium source ionization (absorption rate decreases by 40%), or excessive peptides lead to overly negative charge on the inner wall of the microcapsules (CO2 encapsulation rate decreases by 20%).

[0067] In the preparation of phosphorylated peptide-calcium salt nanocomposites, the pH of the mixture of phosphorylated peptide and calcium salt in water is adjusted to 6.5-7.5. When pH < 6.5, the coordination rate is < 60%, and when pH > 7.5, calcium carbonate decomposes prematurely. The preferred pH is 7.0 ± 0.2, which is the optimal balance point between phosphate group deprotonation and Ca²⁺ coordination.

[0068] In the preparation of phosphorylated peptide-calcium salt nanocomposites, the solid content of the mixture of phosphorylated peptide and calcium salt in water determines the collision frequency of nanoparticles. Too high a concentration leads to aggregation (particle size > 300 nm), while too low a concentration results in low production capacity. The reaction temperature (25-35℃, preferably 30℃) is the critical point that balances coordination kinetics and peptide stability (the hydrolysis rate of phosphate groups in casein phosphopeptides is >15% at >35℃).

[0069] Isomaltose porous framework

[0070] In the process of mixing sugar alcohol matrix materials with water to prepare syrup, heating to 80-90℃ is required for dissolution, followed by vacuum concentration until the moisture content is ≤3%. This temperature range allows the sugar alcohol matrix materials to dissolve rapidly and avoids localized overheating and caramelization. Temperatures >95℃ will lead to the Maillard reaction, producing bitter substances (furfural content >10ppm). This moisture content is the determining factor for the subsequent rapid freezing at -40℃ to form an amorphous glassy state (rather than a crystalline state). When the moisture content is >5%, the ice crystals formed during the freezing process are too large (>50μm), the porosity after drying is <30%, and the disintegration time is extended to >45 seconds.

[0071] In addition, during vacuum concentration (e.g., vacuum degree -0.09MPa), the boiling point of the syrup is reduced to 60-65°C, avoiding the destruction of vitamin D3 by high temperature (its thermal degradation temperature is about 70°C), while reducing energy consumption by about 30%.

[0072] quick-freezing and vacuum drying

[0073] This invention abandons the traditional high-temperature sugar boiling and aeration method, and adopts quick freezing at -40℃ to -30℃ + vacuum drying to protect heat-sensitive components such as vitamin D3. At the same time, it constructs a porous framework (porosity 40-60%) of sugar alcohol matrix (such as isomaltitol), which can achieve industrial production without high-pressure equipment.

[0074] Before quick-freezing, nanocomposite powder, CO2 microcapsule powder, optional acid source particles, and optional edible additives are added to the syrup. The preferred mixing temperature is 40℃±2℃: this temperature is higher than the glass transition temperature (Tg=38℃) of Eudragit S100, placing it in a highly elastic state, giving the microcapsules a certain degree of flexibility and preventing breakage during stirring; simultaneously, it is lower than the critical dissolution temperature of CO2 (above 42℃, the solubility of CO2 in the syrup increases dramatically, leading to leakage). Mixing is carried out under a vacuum of 0.06-0.09 MPa, preferably 0.08 MPa. This vacuum level eliminates residual air bubbles in the syrup (preventing the formation of large pores during subsequent freeze-drying) without causing excessive pressure difference between the inside and outside of the microcapsules, which could lead to rupture (microcapsule breakage rate >25% when pressure difference >0.1 MPa). Mixing is also carried out at a low stirring speed (10-50 rpm, preferably 20 rpm), where the shear force achieves uniform mixing while maintaining the integrity of the microcapsules. When the rotation speed is greater than 50 rpm, the microcapsule breakage rate exceeds 40%, and CO2 is released prematurely. In addition, the order of adding ingredients to the syrup during mixing is nanocomposite, microcapsule, acid, and vitamin: adding nanocomposite first allows it to partially embed into the syrup skeleton, forming an anchoring effect; adding vitamin D3 last prevents its oxidative degradation during stirring.

[0075] The inventors unexpectedly discovered that vacuum mixing not only improves stability but also plays a key role in improving children's compliance. Subsequent clinical studies found that this mixing method results in the microcapsules being distributed in an "island-like" pattern within the tablet, with only the surface microcapsules coming into contact with saliva and producing gas during the oral cavity stage, creating a "gradual microbubble sensation" and avoiding the irritating cough caused by excessive gas production at one time (the incidence rate decreased from 15% to 2%).

[0076] Two-phase collapse mechanism

[0077] In a preferred embodiment, the calcium tablets of the present invention can quickly produce a pleasant microbubble sensation in the oral cavity and achieve localized disintegration and efficient calcium absorption in the small intestine, making them particularly suitable for children, diabetic patients, and people with swallowing difficulties.

[0078] In the oral cavity stage (0-30 seconds): the porous framework of the sugar alcohol matrix breaks down, and trace amounts of solid organic acids react with calcium carbonate to generate CO2 (<0.5mg / tablet), producing a pleasant microbubble sensation. The phosphorylated polypeptide-calcium complex is not released. The CO2 production in the oral cavity and intestinal stages is determined using a modified water displacement gas collection method: the calcium tablet is placed in simulated oral fluid or artificial intestinal fluid, the released gas is collected, and the CO2 content is quantitatively analyzed using a gas chromatograph (TCD detector).

[0079] Intestinal phase (30-120 minutes): pH-responsive microcapsules rupture, releasing the main dose of CO2 (2-3 mg / tablet), which drives the disintegration of the nanocomplex, and the simultaneous release of phosphorylated peptides promotes calcium absorption.

[0080] Raw material composition

[0081] In a preferred embodiment, the raw materials and their composition of the sugar-free self-disintegrating calcium tablets provided by the present invention are shown in Table 1.

[0082] Table 1: Raw materials and composition of exemplary sugar-free self-disintegrating calcium tablets

[0083] Components Content range (wt%) Functional positioning Isomaltitol 85.0-92.0% Porous framework, sweetener Phosphorylated peptide-calcium salt nanocomplex 5.0-10.0% Calcium source + absorption enhancer <![CDATA[CO2 microcapsules (Eudragit S100 coated)]]> 2.0-4.0% Intestinal gas-producing disintegrants Anhydrous citric acid 0.1-0.5% Oral microbubble acid source <![CDATA[Vitamin D3]]> 0.001-0.01% Synergistic calcium supplementation essence 0.2-0.6% Flavor adjustment natural pigments 0.003-0.01% Appearance improvement

[0084] The phosphorylated peptide is specifically casein phosphopeptide (CPP) or phosphorylated serine peptide, and its mass percentage in the nanocomposite is not less than 20% (i.e., the total addition amount is 1.0-2.0 wt%), to ensure that the calcium peptide molar ratio reaches a coordination saturation state of 1:1.5-1:2.5.

[0085] The present invention will be further illustrated below with reference to specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods, and equipment used in the present invention are conventional reagents, methods, and equipment in this technical field.

[0086] The testing methods used in this embodiment are as follows.

[0087] Particle size and zeta potential determination: The particle size distribution (D10, D50, D90) of the nanocomposite was determined at 25℃ using a dynamic light scattering instrument (DLS, Malvern Zetasizer Nano ZS), and the zeta potential was determined by electrophoretic light scattering.

[0088] CO2 encapsulation and retention rates were determined using a combined acid-base titration and gas chromatography method. A quantitative amount of microcapsules was weighed and reacted with acid. The mass of released CO2 gas was measured using a gas chromatograph with a TCD detector (GC-TCD). The encapsulation rate (%) was calculated as (measured CO2 mass / total microcapsule mass) × 100%. The retention rate was calculated based on the change in encapsulation rate before and after the accelerated testing.

[0089] Porosity determination of porous framework: The true density and framework volume were determined by gas displacement method (helium hydrometer, Micromeritics AccuPycII), and the porosity (%) was calculated as (1-apparent density / true density)×100%.

[0090] CO2 production determination (modified water displacement gas collection method + GC-TCD): Place a single calcium tablet in a sealed reaction bottle, add 3 mL of artificial saliva simulation solution at 37℃ (for oral stage) or 50 mL of artificial intestinal fluid (pH 7.4 or pH 6.8) (for intestinal stage), collect the gas and inject it into the GC-TCD for quantitative analysis of CO2 content (carrier gas is helium, chromatographic column is Porapak Q, column temperature is 50℃, detector temperature is 150℃).

[0091] Disintegration performance test (staged dual-media method): Refer to the General Chapter 0921 (disintegration time limit test method) of Part IV of the 2020 edition of the Chinese Pharmacopoeia. Since this calcium tablet is orally disintegrating, a modified static / small cup method (3mL simulated saliva) was adopted to simulate the actual amount of saliva in the oral cavity. (1) Oral disintegration stage: Take 6 tablets and place them in artificial saliva simulation solution (pH 6.8, enzyme-free, 3mL / tube) at 37℃±0.5℃. Record the time for the porous skeleton to completely dissolve and disintegrate and pass through a 100-mesh (pore size 150μm) sieve. This time is recorded as the oral disintegration time limit (seconds). (2) Intestinal disintegration stage: Take the residual suspension or intact microcapsules after the oral stage and place them in artificial intestinal fluid (pH 7.4 or pH 6.8, 500mL) at 37℃±0.5℃. Test at a frequency of 30 times / min and record the time when the microcapsules completely rupture and release CO2 and when the packaging material completely dissolves and breaks down and passes through a 20-mesh (850μm) sieve. This time is recorded as the intestinal disintegration time (minutes).

[0092] Stability testing method: Referring to General Chapter 9001 (Guidelines for Stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Preparations) of Part IV of the 2020 edition of the Chinese Pharmacopoeia, the samples were sealed in aluminum-plastic blister packs with desiccant inside and placed in a constant temperature and humidity chamber for accelerated stability testing: the conditions were temperature 40℃ ± 2℃ and relative humidity RH 75% ± 5%. Samples were taken at the end of 0, 1, 2, 3, and 6 months to detect CO2 encapsulation rate (GC-TCD method), nanocomposite particle size, and vitamin D3 content (HPLC method). The CO2 retention rate (%) after 6 months was calculated as (CO2 content in month 6 / CO2 content in month 0) × 100%.

[0093] Methods for assessing children’s medication adherence and VAS scores: Children aged 3-12 years (sample size n=30) were selected and a single-blind assessment of taste and acceptance was conducted with the informed consent of their guardians. (1) Visual analog scale (VAS score): A 10-point children’s face drawing visual analog scale (0 points indicates extreme aversion / stinginess, 10 points indicates great liking / excellent taste) was used. Children or guardians scored the children based on their oral microbubble sensation, flavor and swallowing smoothness. (2) Active medication rate: The percentage of children who actively completed a single medication administration process without parental coercion or inducement was counted (active medication rate % = number of children who actively took medication / total number of subjects × 100%).

[0094] Calcium ion uptake and cell permeability coefficient (Papp) determination. Caco-2 cell experiment: A Caco-2 monolayer cell model was established, and samples were added for treatment for 2 hours. The calcium ion concentration on the receiver side was measured by ICP-OES, and the apparent permeability coefficient Papp (cm / s) was calculated. SD rat absorption experiment: Healthy male SD rats were selected, randomly divided into groups, and each group was given calcium tablets (calcium dosage 20 mg / kg) by gavage. The amount of calcium excreted in feces and urine was measured within 48 hours, and the apparent calcium uptake (%) was calculated as: (calcium intake - fecal calcium - urinary calcium) / calcium intake × 100%.

[0095] Example 1: Strawberry-flavored sugar-free self-disintegrating calcium tablets for children

[0096] 1. Raw material composition

[0097] Isomaltitol 88.5kg, phosphorylated polypeptide-calcium salt nanocomposite 8.0kg, CO2 microcapsules 3.0kg, anhydrous citric acid 0.3kg, vitamin D3 (1 million IU / g) 0.008kg, strawberry flavor 0.18kg, carmine 0.012kg.

[0098] 2. Preparation steps

[0099] (1) Preparation of nanocomposite: 2.0 kg of phosphorylated serine peptide with a molecular weight of 2000 Da and 6.0 kg of calcium carbonate were mixed in deionized water (solid content 15 wt%), the pH was adjusted to 7.0, and the mixture was stirred at 30 °C for 2 hours to form a nanocomposite solution through coordination self-assembly. The nanocomposite powder was obtained by spray drying (inlet air temperature 120 °C, outlet air temperature 75 °C). The particle size D90 was measured to be 120 nm, and the Zeta potential was -25 to -35 mV.

[0100] (2) Preparation of CO2 microcapsules: Eudragit S100 was dissolved in 95% ethanol to prepare a wall material solution with a concentration of 8 wt%. Coaxial spray drying technology was used, with food-grade CO2 gas (pressure 4.5 MPa, flow rate 2.5 L / min) introduced into the inner channel and the wall material solution introduced into the outer channel, allowing the CO2 gas to be encapsulated by the wall material solution to form microcapsules. The nozzle of the coaxial spray dryer had an inner diameter of 0.5 mm, an outer diameter of 1.2 mm, and a wall thickness of 0.35 mm. The resulting microcapsule particle size was 20-40 μm, and the CO2 encapsulation rate reached 22%.

[0101] (3) Preparation of skeleton syrup: Add isomaltulitol and deionized water to the sugar dissolving pot at a mass ratio of 6:1, heat to 85°C to dissolve, and vacuum concentrate to a moisture content of ≤3% to form syrup (no need for high-temperature sugar boiling).

[0102] (4) Vacuum mixing: Cool the syrup to 40°C, and add nanocomplex powder, CO2 microcapsules, anhydrous citric acid, vitamin D3, flavoring and coloring in sequence. Stir at low speed (20 rpm) for 10 minutes under vacuum (0.08 MPa) to ensure the integrity of the microcapsules.

[0103] (5) Quick-freezing molding: Inject the mixture into the mold and quick-freeze at -40℃ for 2 hours to make the syrup form an amorphous glassy porous structure.

[0104] (6) Vacuum drying: Transfer to a vacuum drying oven and dry for 48 hours at 25°C and 10Pa vacuum until the moisture content drops below 1.5%. Demold to obtain calcium tablets (diameter 12mm, thickness 5mm, tablet weight 1.2g / tablet).

[0105] (7) Packaging: After passing through metal detection, it is packaged in aluminum-plastic blister pack with desiccant inside.

[0106] Performance test results

[0107] Disintegration performance: Take 6 samples and test them according to the disintegration time determination method in the Chinese Pharmacopoeia. The disintegration time of the skeleton in artificial saliva simulated solution (37℃) is 18-25 seconds; the disintegration time of the microcapsules in artificial intestinal fluid (pH7.4, 37℃) is 45-60 minutes. After disintegration, the calcium salt is in a nano-suspension state.

[0108] Stability: After accelerated testing (40℃ / 75%RH / 6 months), CO2 retention rate was 88%, nanocomposite particle size change was <10%, and vitamin D3 content degradation rate was <3%. Gas permeation path tortuosity measured by gas permeation meter was ≥3.5.

[0109] Absorption effect: SD rat experiments showed that calcium absorption rate was 64% higher than that of ordinary calcium carbonate tablets (p<0.01); Caco-2 cell experiments showed that the apparent calcium permeability coefficient (P<0.01) was also higher. appIt is 2.8 times more effective than ordinary calcium carbonate tablets.

[0110] Adherence: The rate of children aged 3-12 years taking medication voluntarily increased from 32% for regular calcium carbonate tablets to 89% (VAS score 8.5 / 10).

[0111] Example 2: Rose Lychee Flavored Adult Sugar-Free Self-Disintegrating Calcium Tablets

[0112] 1. Raw material composition:

[0113] Isomaltitol 87.2 kg, phosphorylated polypeptide-calcium salt nanocomposite 9.0 kg (dual calcium source: containing calcium carbonate and calcium citrate (mass ratio 7:3)), CO2 microcapsules 3.5 kg (Eudragit S100 / FS30D mixed coating), anhydrous citric acid 0.4 kg, vitamin D3 0.01 kg, vitamin C 0.15 kg, rose and lychee flavor 0.6 kg, steviol glycosides 0.14 kg, carmine 0.01 kg.

[0114] 2. Preparation steps

[0115] (1) Preparation of nanocomposite: Same as in Example 1, except that calcium carbonate and calcium citrate in a mass ratio of 7:3 were used instead of calcium carbonate used in Example 1.

[0116] (2) CO2 microcapsule preparation: Same as in Example 1, except that Eudragit S100 and FS30D are mixed at a mass ratio of 7:3 so that the microcapsules begin to dissolve at pH 6.8, which is suitable for middle-aged and elderly people with gastric acid deficiency.

[0117] Steps 3-7 are the same as in Example 1, except for the freeze-drying parameters: quick-freezing temperature -35°C, vacuum drying for 36 hours.

[0118] Performance test results

[0119] Disintegration performance: The disintegration time of the skeleton in artificial saliva simulated solution is 15-20 seconds; the disintegration time of the microcapsules in artificial intestinal fluid (pH 6.8, 37℃) is 30-45 minutes.

[0120] Absorption effect: Apparent calcium permeability coefficient (P) in Caco-2 cell experiments app It is 3.2 times more effective than ordinary calcium carbonate tablets.

[0121] Preliminary clinical trial: After administration to 30 volunteers, peak serum calcium (C) levels were observed. max The peak time (T) increased by 42%, and the peak time (T) was also increased. max This will shorten the journey by 1.8 hours.

[0122] Comparative Example 1 (Popping Candy Process Comparison)

[0123] Prepared according to the traditional popping candy method: isomaltose is boiled at high temperature (150-155℃) and then pressurized with gas (5-7MPa), with a CO2 content of about 0.5 wt%, no phosphorylated peptide-calcium salt nanocomplex, and no enteric microcapsules.

[0124] Test results: CO2 leakage rate >60% in 6-month accelerated test, hard texture, child compliance score 5.2 / 10, calcium absorption rate not significantly different from ordinary calcium carbonate tablets.

[0125] Comparative Example 2 (using only nanocomposite materials, without CO2 microcapsules)

[0126] The formulation and process of Example 1 are identical except that the CO2 microcapsules are omitted.

[0127] Test results: Oral disintegration time > 60 seconds, no pleasurable microbubble sensation; intestinal disintegration relies on erosion, is not propelled by gas, and has a release rate of only 70%.

[0128] Comparative Example 3 (using only CO2 microcapsules, without nanocomposites)

[0129] The formulation and process of Example 1 are the same, except that the phosphorylated polypeptide-calcium salt nanocomposite is omitted, the calcium source is replaced with an equal amount of ordinary calcium carbonate, and everything else is exactly the same.

[0130] Test results: The calcium absorption rate was no different from that of ordinary calcium carbonate tablets, but the bioavailability was low.

[0131] Comparative Example 4

[0132] (1) Preparation of nanocomposite: 1.6 kg of phosphorylated serine peptide with a molecular weight of approximately 2000 Da was mixed with 6.0 kg of calcium carbonate in deionized water, with a solid content of 15%. The pH was adjusted to 6.3-6.5, and the mixture was stirred at 30°C for 2 hours. The remaining spray drying conditions were the same as in Example 1. The obtained nanocomposite had a particle size D90 of approximately 120 nm, and the Zeta potential measured by electrophoretic light scattering was -20.2 mV.

[0133] The remaining steps 2-7 are exactly the same as in Example 1.

[0134] Test results: The CO2 retention rate decreased by approximately 28% in the accelerated test; the gas permeation path tortuosity was <3.0.

[0135] It should be noted that while the preferred embodiments of the present invention are provided in this specification, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. These embodiments are not intended to impose additional limitations on the content of the present invention; their purpose is to provide a more thorough and comprehensive understanding of the disclosure of the present invention. Furthermore, the above-described technical features can be combined with each other to form various embodiments not listed above, all of which are considered to be within the scope of the present invention. Moreover, those skilled in the art can make improvements or modifications based on the above description, and all such improvements and modifications should fall within the protection scope of the appended claims.

Claims

1. A sugar-free, self-disintegrating calcium tablet, characterized in that, Include: A porous framework composed of sugar alcohol matrix materials with vitrification capability; CO2 microcapsules dispersed in the porous framework, wherein the CO2 microcapsules are composed of a pH-sensitive enteric material encapsulating CO2 gas, and the particle size is 10-50 μm. as well as The phosphorylated polypeptide-calcium salt nanocomposite dispersed in the porous framework has a particle size of 50-200 nm and a zeta potential of -25 to -35 mV. It fills the pores and gaps around the CO2 microcapsules in the porous framework, forming electrostatic repulsion and size gradation effect with the CO2 microcapsules to block the diffusion and leakage of CO2 gas.

2. The sugar-free, self-disintegrating calcium tablets according to claim 1, characterized in that, The sugar alcohol matrix material is selected from at least one of isomaltitol and maltitol; The porosity of the porous framework is 40-60%; The sugar alcohol matrix material has a mass percentage of 85.0-92.0% in the sugar-free self-disintegrating calcium tablets.

3. The sugar-free, self-disintegrating calcium tablets according to claim 1, characterized in that, The CO2 microcapsules contain 15-25% CO2 by mass. The CO2 microcapsules have a mass percentage of 2.0-4.0% in the sugar-free, self-disintegrating calcium tablets.

4. The sugar-free, self-disintegrating calcium tablets according to claim 1, characterized in that, The pH-sensitive enteric material is Eudragit S100, or a mixture of Eudragit S100 and Eudragit FS30D in a mass ratio of (6-8):(2-4).

5. The sugar-free, self-disintegrating calcium tablets according to claim 1, characterized in that, The molecular weight of the phosphorylated polypeptide is 1000-3000 Da; The phosphorylated polypeptide is selected from at least one of casein phosphopeptide and phosphorylated serine peptide. The calcium salt is selected from one or more of calcium carbonate and calcium citrate; In the phosphorylated polypeptide-calcium salt nanocomposite, the molar ratio of calcium ions participating in coordination to phosphorylated polypeptides is 1:(1.5-2.5). The phosphorylated polypeptide accounts for no less than 20% of the mass percentage in the nanocomposite. The phosphorylated polypeptide-calcium salt nanocomposite has a mass percentage content of 5.0-10.0% in the sugar-free self-disintegrating calcium tablets.

6. The sugar-free, self-disintegrating calcium tablets according to claim 1, characterized in that, The sugar-free, self-disintegrating calcium tablets also contain solid organic acid particles dispersed in the matrix; The solid organic acid particles are selected from at least one of anhydrous citric acid, malic acid, and tartaric acid, and their mass percentage in the sugar-free self-disintegrating calcium tablets is 0.1-0.5%.

7. The sugar-free, self-disintegrating calcium tablets according to claim 1, characterized in that, The sugar-free, self-disintegrating calcium tablets also contain edible additives; The edible additives are selected from at least one of vitamin D3, flavoring, and coloring.

8. A method for preparing sugar-free, self-disintegrating calcium tablets according to any one of claims 1-7, characterized in that, Includes the following steps: (1) Prepare phosphorylated polypeptide-calcium salt nanocomposite powder and CO2 microcapsule powder respectively; (2) Mix sugar alcohol matrix material with water at a mass ratio of 5:1 to 8:1, heat to 80-90℃ to dissolve, and vacuum concentrate to a water content of ≤3wt% to obtain syrup; (3) Cool the syrup to 40℃±2℃, and under vacuum conditions of 0.06-0.09MPa and 10-50rpm, add the nanocomposite powder, the CO2 microcapsule powder, optional solid organic acid particles and optional edible additives in sequence for vacuum mixing. (4) The mixture obtained in step (3) is rapidly frozen at -40°C to -30°C to form an amorphous glassy porous framework for the sugar alcohol matrix material; (5) The material after quick-freezing is vacuum dried at 20-30℃ and vacuum degree ≤10Pa until the moisture content is less than 1.5wt%, and then demolded.

9. The method according to claim 8, characterized in that, In step (1), the phosphorylated polypeptide-calcium salt nanocomposite is prepared as follows: the phosphorylated polypeptide and calcium salt are mixed in water, the solid content is controlled to be 10-20wt%, the pH is adjusted to 6.5-7.5, and the mixture is stirred at 25-35℃ for 1-3 hours to complete coordination self-assembly. The resulting solution is spray-dried to obtain nanocomposite powder.

10. The method according to claim 8, characterized in that, In step (1), the CO2 microcapsules are prepared as follows: pH-sensitive enteric material is dissolved in an alcohol-based organic solvent to prepare a 5-10 wt% wall material solution; food-grade CO2 gas is introduced into the inner channel at a flow rate of 2-3 L / min under a pressure of 4-5 MPa using coaxial spray drying technology, and the wall material solution is introduced into the outer channel, so that the CO2 gas is encapsulated by the wall material solution to form microcapsules. The inner diameter of the nozzle for coaxial spray drying is 0.3-0.8 mm, the outer diameter is 1.0-1.5 mm, and the wall thickness is 0.2-0.5 mm.